TWST
Twist Bioscience Corporation
Stock
$188.67+0.62 (+0.33%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $432M | $377M | $313M | $245M | $204M | $132M | $90M | $54M | $25M | $11M |
| R&D | $72M | $80M | $91M | $107M | $120M | $69M | $43M | $36M | $20M | $19M |
| SG&A | $290M | $247M | $218M | $190M | $213M | $136M | $103M | $80M | $43M | $26M |
| Operating income | −$145M | −$136M | −$221M | −$217M | −$235M | −$153M | −$140M | −$109M | −$71M | −$58M |
| Non-operating income | $9.1M | $59M | $13M | $14M | $6.5M | −$1.3M | $530K | $1.5M | −$435K | −$548K |
| Pretax income | −$136M | −$77M | −$208M | −$203M | −$228M | −$154M | −$140M | −$107M | −$71M | −$59M |
| Taxes | $864K | $719K | $560K | $1.2M | −$10M | −$1.9M | $382K | $292K | $242K | $280K |
| Net income | −$137M | −$78M | −$209M | −$205M | −$218M | −$152M | −$140M | −$108M | −$71M | −$59M |
| Diluted EPS | −$2.23 | −$1.30 | −$3.60 | −$3.60 | −$4.04 | −$3.15 | −$3.57 | −$3.92 | −$25.51 | −$24.49 |
| Diluted shares | — | 59.8M | 58.0M | 56.9M | 53.9M | 48.3M | 39.2M | 27.5M | 2.79B | 2.42B |
| Revenue growth | — | +20.3% | +27.7% | +20.4% | +53.8% | +46.9% | +65.7% | +113.9% | +136.2% | — |
| Operating margin | −33.6% | −36.2% | −70.6% | −88.6% | −115.3% | −115.4% | −155.5% | −200.1% | −277.5% | −543.2% |
| Net margin | −31.7% | −20.6% | −66.7% | −83.5% | −107.0% | −114.9% | −155.3% | −198.0% | −280.2% | −550.8% |